Table S3. Oligonucleotides utilized in this study.

Oligonucleotide name	Sequence (5'-3')	Restriction site	Purpose
A (F)**	GCCTTGGCCTGGGCTAGCCTG	*Nhe*I**	Site-directed mutagenesis
B (R)*	TCTGCCCACGGAAGGTGCCCGTAGGGCG	----	Site-directed mutagenesis
C (R)*	CACCGCATGACGTCTGCCCACGGAAGGTGC	----	Site-directed mutagenesis
D (F)**	GGCAAAGCTTGGGTGCTTCTGGC	*Hind*III**	Site-directed mutagenesis
S (R) *	CACGAGGCTTCGCACGCACC	----	Sequencing
pMAJIIc (F) **	ATCGCTAGCATGACGCTGTCCCGGGGC	*Nhe*I**	Complementation/mCherry fusion
pMAJIIc (R) **	GTCACTCGAGCTCGACGCTGATGGTCTGGGT	*Xho*I	mCherry fusion
R4296	CACGAGGCTTCGCACGCACC	-	Sequencing
F4296	GGCAAAGCTTGGGTGCTTCTGGC	-	Sequencing

*F, Forward; R, Reverse. Oligonucleotides synthesized by SIGMA-ALDRICH BRASIL.

** Underlined regions represent added restriction sites;

B/C and R1/F2 oligonucleotides blue sequences are complementary to sequences in red of its pairing primer.